Kornimate/medical-research-clean huggingface dataset:
cognitive exercise therapy approach (bety) in parkinson's disease

Conditions: Parkinson Disease

Summary: considering the impact of motor and non-motor findings on movement problems in the disease management of people living with pd, biopsychosocial evaluation and treatment approaches are essential. however, there are not many studies investigating the impact of a biopsychosocial-based exercise approach on the biopsychosocial characteristics of individuals in pd management. the cognitive exercise therapy approach (bety), an innovative exercise approach based on the biopsychosocial model, has been developed with the participation of individuals with rheumatism in exercise sessions for many years. this study investigated the effects of the bety, a supervised biopsychosocial model-based exercise intervention, on cognitive status, physical activity, balance, and biopsychosocial status in people living with pd.


Eligibility criteria:
inclusion criteria: * diagnosed with idiopathic parkinson's disease * between 1-3 at home according to modified hoehn and yahr staging (mh\&y) exclusion criteria: * individuals who were diagnosed with dementia before parkinson's diagnosis * had undergone deep brain stimulation * diagnosed with psychiatric or additional neurological diseases * had limited physical activity due to orthopedic problems or previous neurological diseases * had communication problems

Keywords: biopsychosocial model depression disease management exercise parkinsons' disease quality of life
clinical study of 18f-fapi-rgd in breast tumors

Conditions: Breast Tumors

Summary: the goal of this observational study is to learn about the value of 18f-fapi-rgd pet/ct imaging in breast tumors. participants will undergo clinical evaluation and 18f-fapi-rgd pet/ct examination.

breast cancer is the most common malignant disease in women worldwide.early detection, accurate diagnosis and staging are the keys to effective treatment for breast cancer patients.18f-fdg pet/ct has become an important imaging method for the diagnosis and staging of breast cancer.however,fdg pet has certain limitations, including false-positive uptake for acute and chronic infections and false-negative uptake for less aggressive histological subtypes of breast cancer.in a number of studies, 68ga-fapi pet was positively correlated with the pathological grade and end-stage of primary breast cancer lesions, and suvmax could predict tumor grade, final stage and lymph node metastasis. compared with 18f-fdg,68ga-fapi pet/ct had higher specificity and accuracy in judging lymph node metastasis.integrin αvβ3 is highly expressed in neovascular endothelial cells and tumor cells including breast cancer, and plays an important role in regulating tumor growth, angiogenesis, local invasion and metastasis potential.the use of integrin αvβ3 specific imaging probes derived from rgd peptides in breast cancer patients has also been reported. several studies have confirmed that the heterodimer is superior to the corresponding monomer due to the polyvalent effect, thus improving the binding affinity and increasing the number of effective receptors.in order to simultaneously target fap and integrin αvβ3, we synthesized the heterodimeric peptide fapi-rgd from fapi and rgd.fapi-rgd is a heterodimeric peptide that targets fap and αvβ3-integrin receptors. 68ga-fapi-rgdpet/ct imaging has been used in clinical imaging studies in patients with a variety of tumors.therefore, we plan to use 18f-fapi-rgd pet/ct imaging for the diagnosis and treatment of breast cancer, and preliminary experiments have confirmed that this examination has a good imaging effect.

Eligibility criteria:
inclusion criteria: * age 18 and above * no gender difference * patients who have been diagnosed with, or are clinically highly suspected of, breast tumors and have had no other treatment within 3 months * tumor size (t), lymph node status (n), and overall clinical stage of diagnosed patients were determined according to the american joint committee on cancer criteria revised in 2010 exclusion criteria: * patients with a second primary tumor * pregnant or breastfeeding * severe liver or kidney disease * claustrophobia or other pet/ct scan contraindications
graft patency of qfr-guided versus angio-guided coronary artery bypass grafting

Conditions: Coronary Artery Disease; Ischemic Heart Disease

Summary: coronary artery bypass grafting(cabg) is the golden standard for severe coronary artery disease(cad), the current surgery strategy is mainly based on coronary angiography(cag), but many trials of pci have shown that visually stenosis in cag may not have functional significance. the aim of this study is to investigate if the quantitative flow ratio (qfr) can be adopted in cabg and achieve a better graft patency.

cabg is the major treatment of three vessels or left main disease. cag is the main basis on choosing the vessels to graft, however, some of the grafts occluded shortly after surgery due to competitive flow, these vessels may not be significantly stenosis in functional assessment such as fractional flow reserve (ffr). quantitative flow ratio (qfr) is a novel method for evaluating the functional significance of coronary stenosis. comparing to ffr, there is no need for pressure wire or atp when performing qfr. this study plan to investigate the clinical effect of qfr in cabg, all patients included will be allocated 1:1 into two groups: qfr-guided and angio-guided, qfr-guided group will be performed a cabg based on the result of qfr, the other group will be based on heart team discussion of cag, cta will be adopted to evaluate the 1 year graft patency.

Eligibility criteria:
inclusion criteria: * patients with evidence of angina pectoris * left main or three vessels disease, have the indication for cabg after discussion of the heart team * at least one main vessels stenosis on 40%-70% exclusion criteria: * former cardiac surgery patients * need to perform other cardiac or major surgery( i.e. valve surgery, carotid endarterectomy * emergent cabg * acute myocardial infarction time less than 7 days * life expectancy less than 3 years

Keywords: quantitative flow ratio coronary artery bypass grafting graft patency
temsirolimus and cetuximab in patients with advanced or metastatic solid tumors

Conditions: Patients With Advanced or Metastatic Solid Tumors

Summary: cetuximab is an egfr inhibitor that has shown efficacy alone or in combination in colorectal cancer or head and neck cancer in several phase ii/iii studies. temsirolimus is a new mtor inhibitor that has shown interesting results in several phase i/ii studies in advance kidney cancer of bad prognosis. study hypothesis is that combination of those two compounds and the inhibition of two pathways at the same time will have more efficiency on tumoral growth than the inhibition of those pathways in isolation.


Eligibility criteria:
inclusion criteria: * patients with malignant tumor confirmed histologically or cytologically who does not respond to usual therapeutics or for whom there is no curative treatment * age \>/= 18 years * ecog 0 or 1 * life expectancy \>/= 12 weeks * grade \</=1 for all adverse effects related to previous therapy or surgery (except for alopecia) * appropriate organic functions as defined: * asat and alat \</= 2.5xlsn or asat and alat \</= 5xlsn in case of inappropriate hepatic function due to the underlying disease * bilirubin \</= 1.5xlsn * albumin \>/= 3.0 g/dl * neutrophil counts (pnn) \>/= 1 500/ml * platelets \>/= 100 000/ml * hemoglobin \>/= 9.0 g/dl * creatinin \</= 1.5xlsn * cooperative patients able to respect the protocol exclusion criteria: * treatment by chemotherapy, radiotherapy, surgery or the two compounds of the study within 4 weeks before the inclusion * previous treatment with an association of mtor inhibitor or egfr inhibitor * diagnosis of a secondary cancer within the last 3 years except for a basal-cell carcinoma, cutaneous spinocellular cancer or in situ carcinoma well treated * grade \>/= 2 nephropathy according to nci ctcae * current treatment with curative dose of coumadin or heparin of low molecular weight * previous uncontrolled brain metastases, medullar compression or carcinomatosis meningitis or any proof of leptomeningeal pathology or metastasis. * presence of one og those pathologies during the last 12 months before the inclusion: * myocardial infarction * angina pectoris * bypass of coronal or peripheral arteries * heart failure * stroke * cerebral bleeding * pulmonary embolism * grade 3 bleeding according to nci ctcae criteria less than 3 weeks before treatment start * uncontrolled high blood pressure (\>150/100mhhg) * grade \>/=2 heart rate disorder, atrial fibrillation whichever the grade, lengthen of qtc \>450 msec for male or \>470 msec for female. * patients hiv positive * pregnant or breastfeeding woman * patients with psychiatric disorder * active alcoholism * previous pulmonary interstitial disease * previous hypersensitivity to antihistamine treatment and/or medical contraindication for an antihistamine or corticoid treatment
lower dose decitabine (dac)-primed tc (carboplatin-paclitaxel) regimen in ovary cancer

Conditions: Primary Malignant Neoplasm of Ovary; FIGO Stages II to IV

Summary: ovarian cancer is the most lethal gynecological cancer and the 5th leading cause of cancer death in women. most patients are typically diagnosed with advanced-stage disease. platinum-paclitaxel regimen has been widely adopted as a standard first-line treatment for advanced ovarian cancer. multiple collaborative randomised phase iii trials evaluating the addition of a third chemotherapy agent, maintenance therapy or alternative taxanes failed to demonstrate significant improvements over a standard carboplatin/taxane doublet. decitabine (dac), one major dna demethylating agent, has been approved for treatment of preleukemic hematological disease myelodysplastic syndrome (mds) by the food and drug administration. past trials of these with high doses, i.e., the use of maximal tolerated dose, for patients with solid tumors showed a low therapeutic index, due to extreme toxicities that have probably confounded the ability to document the true clinical response. low dose dna demethylation agent decitabine (dac) can resensitize the therapeutic indexes of resistent ovary cancer cells in vivo and in vitro. the investigators hypothesized that dac-triggered epigenetic reprogramming of tumor cells and possible immune cells could induce pronounced long-dated clinical effect by chemosensitization- and immunopotentiation-driven maximal eradicating roles on the minimal/residual lesions in primary patients with poor prognosis.

given the poor prognosis and the currently existed therapeutic strategies, the investigators will perform a prospective, randomized, phase ii to iii, intergroup trial to compare carboplatin plus paclitaxel (tc) with the dac-primed tc (dtc) regimen in previously untreated patients with stage ii to iv ovarian cancer.

Eligibility criteria:
inclusion criteria: * patients with histologically confirmed international federation of gynecology and obstetrics (figo) stages ii to iv fallopian tube cancer, or primary peritoneal cancer. if only the results of cytological examinations were available, patients needed to have the following criteria: a cytological diagnosis of adenocarcinoma; an abdominal mass more than 2 cm in diameter on abdominal images; and a ca125 to carcinoembryonic antigen (cea) ratio10 of more than 25, or no evidence of gastrointestinal cancer if ca125/cea ratio was less than or equal to 25. previous chemotherapy was not allowed. * all patients had to be at least 18 years of age, to have an eastern cooperative * oncology group (ecog) performance status of 0-3, and were required to have adequate hematologic, renal, and hepatic function. exclusion criteria: * patients were excluded if they had an ovarian tumour with a low malignant potential, or synchronous or metachronous (within 5 years) malignant disease other than carcinoma in situ.
serial epstein-barr virus dna surveillance in nasopharyngeal carcinoma patients

Conditions: Nasopharyngeal Carcinoma

Summary: endemic nasopharyngeal carcinoma (npc) is invariably associated with epstein-barr virus (ebv) infection. plasma ebv dan detected by polymerase chain reaction (pcr)-based assays can provide important informations of disease screening, disease relapse, and risks classification. in this study, the investigators will explore the impact of serial plasma ebv dna during chemotherapy and radiotherapy on initial tumor response and long-term survival in patients with non-metastatic nasopharyngeal carcinoma


Eligibility criteria:
inclusion criteria: 1. patients with newly histologically confirmed non-keratinizing carcinoma (according to who histological type) 2. no evidence of distant metastasis (m0) 3. receive standard radical treatment 4. not exhibiting overt psychopathology, and willing to participate and written informed consent was obtained exclusion criteria: 1. who type keratinizing squamous cell carcinoma or basaloid squamous cell carcinoma. 2. treatment with palliative intent 3. previous chemotherapy or radiotherapy (except non-melanomatous skin cancers outside the intended rt treatment volume) 4. severe intercurrent disease

Keywords: plasma ebv dna nasopharyngeal carcinoma longitudinal surveillance
efficacy and safety of oral ibrexafungerp (scy-078) vs. placebo in subjects with acute vulvovaginal candidiasis

Conditions: Candida Vulvovaginitis

Summary: this is a phase 3, randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral ibrexafungerp (scy-078) compared to placebo in female subjects 12 years and older with avvc.

subjects who meet all of the inclusion and none of the exclusion criteria will be enrolled into the study and will be randomized in a 2:1 ratio to either oral ibrexafungerp or ibrexafungerp matching placebo, as follows: * oral ibrexafungerp 300-mg dose bid (bis in die) for 1 day * oral ibrexafungerp matching placebo bid for 1 day this is a randomized, double-blind study. approximately 366 eligible subjects will be enrolled and randomized in a 2:1 ratio to one of the two study treatment groups. subjects will be followed for assessments of efficacy and safety for approximately one month after study drug administration. the design of this study is identical to vanish 303 study: nct03734991

Eligibility criteria:
inclusion criteria: * subject is a postmenarchal female subject 12 years and older * subject has a diagnosis of symptomatic avvc at baseline including a positive microscopic examination with 10% potassium hydroxide (koh) in a vaginal sample revealing yeast forms (hyphae/pseudohyphae) or budding yeasts, and vaginal ph (≤4.5) exclusion criteria: * subject has any vaginal condition other than avvc that may interfere with the diagnosis or evaluation of response to therapy, such as suspected or confirmed concurrent causes of vulvovaginitis and/or cervicitis (mixed infection) * need for systemic and/or topical (vaginal) anti fungal treatment, including prescription or over-the-counter products during the study and treatment for vulvovaginal candidiasis (vvc) 28 days prior to randomization. * subject has uncontrolled diabetes mellitus. * subject has a vaginal sample with ph \>4.5. * subject has a history of or an active cervical/vaginal cancer.

Keywords: vaginitis yeast infection
evaluation of continuous glucose monitoring in participants with type 2 diabetes mellitus (mk-0000-258 am2)

Conditions: Type 2 Diabetes Mellitus

Summary: this trial will attempt to develop the use of continuous glucose monitoring (cgm) as a tool for the evaluation of both new and existing pharmacological treatments for type 2 diabetes, using the twice daily administered dipeptidyl peptidase-4 (dpp4) inhibitor, vildagliptin as a probe. the primary hypothesis is that two weeks of treatment with 50 mg of oral vildagliptin, twice daily will lead to a statistically significant decrease in 24 hour weighted-mean glucose (wmg) relative to placebo.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of type 2 diabetes mellitus on a clinical regimen that is metformin alone, up to a maximum of 3 gram per day, on a background of lifestyle measures, and has a hemoglobin a1c at screening of \> 7%. * if on antihyperglycemic therapy with both metformin and sulfonylurea with a screening visit/visit 1 hemoglobin a1c of \>= 6.5% and =\< 7.5%, should then discontinue sulfonylurea usage and undergo washout of sulfonylurea. exclusion criteria: * history of either stroke, chronic seizures or major neurological disorder within the last 6 months. * untreated hypertension with a blood pressure of \> 160/95 mmhg. * history of neoplastic disease within the past 5 years. * history of hypersensitivity to vildagliptin or other dpp4 inhibitors. * had major surgery, or donated or lost 1 unit (500 ml) of blood, or participated in another investigational study within 4 weeks prior to screen. * used any illicit drug or abusively used alcohol within the past 3 months.
nebulized corticosteroid for post extubation stridor in children

Conditions: Stridor

Summary: the purpose of this study is to evaluate the efficacy and adverse effect of nebulized corticosteroid to prevent post-extubation stridor in children.

the guideline for prevention and treatment of post-extubation stridor in children is inconclusive include nebulized epinephrine and intravenous corticosteroid. nebulized corticosteroid is alternative treatment for viral croup. the rationale of this study to evaluate the efficacy of nebulized fluticasone propionate to prevent pediatric post-extubation stridor

Eligibility criteria:
inclusion criteria: * children age between 1 month old - 18 year old who was intubated exclusion criteria: * palliative care * anatomical abnormalities of airway; subglottic stenosis * neuromuscular disease with negative inspiratory force \< - 30 mmhg * need positive pressure after extubation
the effect of arterial oxygen parameters on antioxidant parameters

Conditions: Cardiovascular Diseases

Summary: we aimed to measure the changes in your blood values caused by different but safe oxygen values used by us during your heart surgery under laboratory conditions.

hyperoxia is often preferred due to the risk of tissue hypoxia that may develop in cardiac surgery. it is thought that with hyperoxemia, ischemia reperfusion damage increases, microcirculation is impaired and tissue oxygenation is impaired.oxidative damage occurs in cases of increased oxidative stress and impaired antioxidant balance.it was aimed to investigate oxidative damage by recording modified albumin and thiol disulfide in blood simultaneously by recording arterial oxygen levels at determined times during cardiac surgery.

Eligibility criteria:
inclusion criteria: * patient scheduled for cardiac surgery * asa\>3 * aged 18-75 years exclusion criteria: * those with valvular disease * ef\<%40 * bmi\>40 kg/m2 * presence of arrhythmia that impairs hemodynamics * previous history of cerebrovascular * diagnosed with end-stage organ failure

Keywords: cardiovascular surgery antioxidant tiyol-disülfid homeostasis ischemia modified albumin
randomized, single blind, placebo controlled, to evaluate efficacy and safety of polidocanol injectable foam for treatment of symptomatic, visible varicose veins with sfj incompetence

Conditions: Varicose Veins

Summary: the purpose of this study is to evaluate the effectiveness of polidocanol injectable foam in the relief of symptoms, improvement of appearance, and overall effectiveness and safety in the treatment of varicose veins compared to placebo.

the purpose of this study is to evaluate the efficacy of polidocanol injectable foam vs placebo treatments in relief of symptoms using two disease specific questionnaires, establishment of a minimally important difference (mid) for the questionnaires, improvement in the appearance of visible varicosities by a patient and medical assessments aided by pre and post treatment photographs, and a central independent assessor evaluating pre and post treatment photographs. in addition, the study will evaluate the efficacy of polidocanol injectable foam vs the placebo treatment in the elimination of sfj reflux or occlusion of the treated vein, and to determine whether the placebo procedure blinds the patient to treatment assignment.

Eligibility criteria:
inclusion criteria: * males and females 18-65 years old * veines sym score less than 75 points * varicose vein clinical classification ceap 2, 3, 4, or 5 * incompetence of sfj associated with incompetence of the gsv or other major accessory vein * superficial venous disease manifested by both symptoms and visible varicosities * ability to comprehend and sign an informed consent document and completed study questionnaires in english exclusion criteria: * incompetence of the ssv which substantially contributes to the filling of visible varicose veins * current or previous deep vein thrombosis * leg obesity * peripheral arterial disease in the leg to be treated * reduced mobility * planned prolonged travel with limited mobility with in 4 weeks of treatment * history of pulmonary embolism or stroke * major surgery, prolonged hospitalization or pregnancy within 3 months * current anticoagulation therapy (within 7 days of enrollment) * participation in a clinical study involving a investigational product within 3 months * major co-existing disease or clinically significant laboratory abnormalities * known allergic response to polidocanol or heparin or severe and/or multiple allergic reactions * women of childbearing potential not using effective contraception one month prior to enrollment and/or unwilling to continue while on study * pregnant or lactating women * current alcohol or drug abuse

Keywords: varicose veins
maintenance treatment vs. stepwise drug discontinuation in first-episode schizophrenia

Conditions: Schizophrenia; Psychoses

Summary: after one year neuroleptic maintenance treatment in patients with first episode schizophrenia, neuroleptic treatment will be continued vs. stepwise discontinued (randomized design) over a period of 1 year. under both conditions prodrome based early intervention take place.

after one year neuroleptic maintenance treatment in patients with first episode schizophrenia, neuroleptic treatment will be continued vs. stepwise discontinued (randomized design) over a period of 1 year. under both conditions pharmacologic early intervention strategies in case of early sign of relapse will be applied.

Eligibility criteria:
inclusion criteria: * patients after 1 year of maintenance treatment after their first-episode in schizophrenia (according icd-10 f20) * age between 18 and 55 * informed consent * one year neuroleptic maintenance treatment * reaching stable course exclusion criteria: * residence outside of the catchment area * legal reasons * insufficient knowledge of the german language * substance abuse or addiction * pregnancy * serious physical illness * organic brain disease * contraindication to neuroleptic treatment

Keywords: schizophrenia first episode neuroleptic maintenance treatment drug discontinuation prodrome based early intervention